PTC Therapeutics prices $500M convertible notes to refinance 2026 debt
PTC Therapeutics announced pricing of $500 million in 0% convertible senior notes due 2031, with net proceeds to refinance $222 million of 2026 convertible notes. The offering includes a 40% conversion premium and represents a refinancing strategy to extend debt maturity while maintaining financial flexibility.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day